Skip to main content


Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Baseline metabolic profiles of early rheumatoid arthritis patients achieving sustained drug-free remission after initiating treat-to-target tocilizumab, methotrexate, or the combination: insights from systems biology

Fig. 2

Pathway analysis within the identified metabolites in the (a) tocilizumab plus methotrexate, (b) tocilizumab, and (c) methotrexate strategy arms. Metabolites depicted in red nodes have, on average, lower concentration in the sDFR group compared to controls; those depicted in green nodes have a higher concentration. *p ≤ 0.10, **p ≤ 0.05, ***p ≤ 0.01. Metabolites not included in the top three most relevant pathways are not displayed

Back to article page